Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | HPGD | P15428 | 4/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.35 |
| ▸ | TARBP2 | Q15633 | 3/20 | 0.35 |
| ▸ | FUCA1 | P04066 | 3/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.35 |
| ▸ | GLB1 | P16278 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | PDCD4 | Q53EL6 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 2/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3016094 | 0.90 | ALDH1A1 (0.41) | ALDH1A1KDM4EHTTSMN1; SMN2HPGD | |
| SCHEMBL3021173 | 0.85 | ALDH1A1 (0.38) | ALDH1A1KDM4EHTTHPGDTSHR | |
| SCHEMBL3016916 | 0.81 | CYP1A2 (0.36) | ALDH1A1KDM4EHTTSMN1; SMN2HPGD | |
| SCHEMBL13132170 | 0.80 | CYP1A2 (0.40) | ALDH1A1KDM4ESMN1; SMN2HPGDCYP1A2 | |
| SCHEMBL3004679 | 0.78 | ALDH1A1 (0.35) | ALDH1A1KDM4EHTTSMN1; SMN2HPGD | |
| SCHEMBL3477651 | 0.78 | ALDH1A1 (0.48) | ALDH1A1KDM4EHTTSMN1; SMN2HPGD | |
| SCHEMBL2108554 | 0.76 | L3MBTL1 (0.51) | ALDH1A1KDM4ESMN1; SMN2HPGDTSHR | |
| SCHEMBL3019716 | 0.75 | MAPT (0.39) | ALDH1A1KDM4EHTTSMN1; SMN2HPGD | |
| SCHEMBL862383 | 0.72 | CYP1A2 (0.49) | ALDH1A1KDM4ESMN1; SMN2HPGDTSHR | |
| SCHEMBL842355 | 0.71 | DPP4 (0.42) | ALDH1A1KDM4EHTTHPGDTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2195310-B1 | LUMINESCENT LANTHANIDE (III) CHELATES, CHELATING AGENTS AND CONJUGATES DERIVED THEREOF | WALLAC OY (FI) | 2016-06-01 | — | — | EP | disclosed |
| US-8221719-B2 | Luminescent lanthanide (III) chelates, chelating agents and conjugates derived thereof | WALLAC OY (FI) | 2012-07-17 | — | — | US | disclosed |
| US-20100204442-A1 | Luminescent lanthanide (III) chelates, chelating agents and conjugates derived thereof | WALLAC OY (FI) | 2010-08-12 | — | — | US | disclosed |
| EP-2195310-A1 | LUMINESCENT LANTHANIDE (III) CHELATES, CHELATING AGENTS AND CONJUGATES DERIVED THEREOF | Wallac OY (FI) | 2010-06-16 | — | — | EP | disclosed |
| WO-2009030819-A1 | LUMINESCENT LANTHANIDE (III) CHELATES, CHELATING AGENTS AND CONJUGATES DERIVED THEREOF | WALLAC OY (FI) | 2009-03-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204442-A1 | Luminescent lanthanide (III) chelates, chelating agents and conjugates derived thereof | LNPEP, SLC39A3, LAP3 | ALDH1A1 4545/4885KDM4E 2737/4885HTT 1969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.